Sartorius AG

Sartorius AG

SARTF
Sartorius AGUS flagOther OTC
228.02
USD
+15.22
- -
15.74BMarket Cap
Sartorius AG
SARTF
(Other OTC)

Recent

price

228.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.67
10.75
12.4
11.61
13.07
16.35
19.01
20.54
22.9
26.71
34.14
50.42
61.02
49.63
49.01
51.24
39.47
Revenue per Share
0.6
0.61
0.71
0.77
0.71
1.85
1.51
1.68
2.07
2.29
3.07
4.66
9.91
3.01
1.22
2.24
3.1
Basic EPS, GAAP
1.05
0.4
-0.14
1.51
1.9
1.84
2.49
3.02
3.58
5.52
7.48
12.76
10.73
4.3
8.21
5.72
5.66
Free Cash Flow per Basic Share
0.14
0.15
0.2
0.24
0.25
0.35
0.38
0.45
0.5
0.62
0.35
0.71
1.26
1.43
0.74
0.74
0.73
Dividend per Share
4.06
4.5
4.9
5.39
5.84
7.57
8.48
9.03
10.83
11.85
15.08
18.42
29.08
30.22
40.05
39.2
40.88
Book Value per Share
-1.84
-2.29
-2.65
-2.65
-2.25
-1.42
-2.27
-6.78
-4.72
-4.64
-17.42
-17.5
-14.79
-50.24
-39.17
-37.53
-35.56
Tangible Book Value per Share
68
68
68
68
68
68
68
68
68
68
68
68
68
68
69
69
69
Basic Weighted Avg Shares
659
733
846
792
891
1,115
1,300
1,405
1,566
1,827
2,336
3,449
4,175
3,396
3,381
3,538
2,738
Sales/Revenue/Turnover
10.93
14.51
14.53
14.65
14.6
18.99
19.05
18.72
19.2
19.89
21.89
27.06
27.29
16.02
12.93
16.09
17.82
Operating Margin (%)
32
33
41
48
55
59
76
98
113
133
180
231
287
342
416
420
320
Depreciation Expense
41
42
49
52
48
126
103
115
141
157
210
319
678
206
84
155
215
Net Income, GAAP
35.13
33.21
31.59
30.71
33.65
31.9
28.96
20.81
27.05
27.85
29.47
36.12
22.73
24.85
26.45
31.6
31.87
Effective Tax Rate (%)
6.17
5.67
5.74
6.62
5.44
11.33
7.92
8.17
9.03
8.58
9
9.25
16.24
6.05
2.48
4.38
7.86
Profit Margin (%)
40
48
34
146
187
206
223
278
273
188
338
250
220
627
669
-201
199
Working Capital
207
271
247
369
379
366
452
887
895
881
1,892
1,738
1,986
5,023
4,167
3,356
3,648
LT Debt
327
366
404
450
498
645
737
807
973
1,093
1,380
1,720
2,659
2,758
3,898
3,867
3,998
Total Equity
7.87
11.15
11.43
9.79
9.67
14.47
14.64
13.26
11.37
12.23
12.36
15.65
18.53
5.93
3.79
4.59
3.98
Return on Invested Capital (%)
9.82
6.27
5.79
5.29
4.33
10.47
5.81
5.36
5.12
5.14
4.84
6.28
10.46
3.46
2.01
2.39
3.4
Return on Capital (%)
14.8
14.23
15.13
14.94
12.67
27.59
18.76
19.16
20.81
20.21
22.81
27.83
41.73
10.13
3.48
5.66
7.86
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
926
964
404
LT Borrowings
3,184
3,169
3,487
LT Finance Leases
172
168
162
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
13,227
13,528
12,862

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,766
1,923
1,643
Cash, Cash Equivalents & STI
552
600
307
Accounts Receivable, Net
225
304
306
Inventories
792
827
832
Total Current Liabilities
1,967
2,113
1,444
Payables & Accruals
- -
- -
- -
ST Debt
926
964
404
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.65%
24.7%
-0.78%
Free Cash Flow
22.27%
11.45%
-30.23%
Net Income, GAAP
18.11%
24%
84.4%
Sales/Revenue/Turnover
13.49%
10.85%
4.66%
Total Cash Common Dividend
16.23%
28.58%
0.2%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
820
861
794
907
3,381
2025
883
884
- -
928
3,538
2026
899
912
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.53
0.34
0.12
- -
1.22
2025
0.7
0.47
- -
- -
2.24
2026
0.81
0.95
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.74
2025
- -
- -
- -
- -
0.74
2026
0.73
- -
- -
- -
- -
Business
Sartorius AG is an international supplier of laboratory and bioprocess technology headquartered in Göttingen, Germany, founded in 1870. The company’s operations are divided into two main divisions: Bioprocess Solutions and Lab Products & Services. Its Bioprocess Solutions division specializes in single-use technologies including filters, bags, cell culture media, and components for filtration, fluid management, fermentation, and purification processes used in biotech and pharmaceutical manufacturing. The Lab Products & Services division offers laboratory instruments and consumables such as lab balances, pipettes, water purification systems, weighing accessories, cell analysis instruments, reagents, and software for lab data and fleet management. Sartorius serves the life sciences research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries worldwide through about 60 production and sales sites. The company’s offerings include biologics testing, bioprocess consulting and engineering, instrument service and validation, and advanced cell culture media. In 2025, Sartorius completed the acquisition of MatTek Corp, a developer of human cell-based microtissues and 3D tissue models, expanding its cell technology portfolio in its Lab Products & Services division to accelerate drug development and reduce animal testing. This acquisition strengthens Sartorius's portfolio of cell analysis instruments, reagents, and AI-supported data models by integrating advanced human tissue models. Sartorius continues to pursue strategic acquisitions and alliances to broaden its innovative solutions in both lab instruments and bioprocess technologies. The company is a leading partner to the global biopharmaceutical industry, focusing on enabling the development and manufacture of biotech medications, vaccines, and cell and gene therapies. Sartorius has a strong commitment to sustainability, with its German sites powered by 100% renewable electricity since 2021. It employs around 13,500 people globally and generated approximately €3.4 billion in sales revenue in 2024. Sartorius maintains a robust global footprint with headquarters in Germany and key operational and production sites, including facilities in the US and Slovakia associated with the MatTek integration. Sartorius AG is listed on the Frankfurt Stock Exchange and DAX index under ticker SARTF. The company's ongoing strategy emphasizes expanding its technological capabilities and market reach through continuous innovation and targeted acquisitions in the life sciences and bioprocess markets.

Company News

  • Reviewing Integra LifeSciences (NASDAQ:IART) & Sartorius (OTCMKTS:SARTF)

  • Sartorius Aktiengesellschaft (SOAGY) Analyst/Investor Day Transcript

  • Sartorius Aktiengesellschaft (SOAGY) Q4 2025 Earnings Call Transcript

  • Critical Survey: ClearPoint Neuro (NASDAQ:CLPT) vs. Sartorius (OTCMKTS:SARTF)

  • Sartorius: Consistent Performance And Market Resurgence - Valuation Falls

  • 7 Stocks Taking The Next Step To Be On Offense

  • Sartorius Aktiengesellschaft (SOAGY) Q3 2025 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (SARTF) Q2 2025 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (SARTF) Q1 2025 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (SARTF) Q4 2024 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (SARTF) Q3 2024 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (SARTF) Q1 2024 Earnings Call Transcript

  • SARTORIUS (SARTF) Upgraded to Strong Buy: Here's What You Should Know

  • Sartorius Aktiengesellschaft (SARTF) Q4 2023 Earnings Call Transcript

  • 10 stocks for investors looking for ‘wonderful companies at a fair price'

  • SARTORIUS (SARTF) Q3 Earnings Lag Estimates

  • Sartorius Aktiengesellschaft (SARTF) Q2 2023 Earnings Call Transcript

  • Sartorius: A German Champion With A Discounted Price

  • Sartorius Aktiengesellschaft (SARTF) Q1 2023 Earnings Call Transcript

  • Sartorius AG: Combating And Benefiting From Eroom's Law